Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 15/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | FURIN | P09958 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26857799 | 0.90 | AKR1C3 (0.51) | FFAR4SLC6A4AKR1C3AKR1C1SLC6A2 | |
| SCHEMBL22256603 | 0.86 | FFAR4 (0.50) | FFAR4PARP10FURIN | |
| SCHEMBL22252621 | 0.86 | FFAR4 (0.50) | FFAR4PARP10FURIN | |
| SCHEMBL22578255 | 0.86 | PARP10 (0.46) | FFAR4PARP10FURIN | |
| SCHEMBL22463663 | 0.86 | PARP10 (0.46) | FFAR4PARP10FURIN | |
| SCHEMBL22252517 | 0.86 | FFAR4 (0.50) | FFAR4PARP10FURIN | |
| SCHEMBL22578254 | 0.86 | PARP10 (0.46) | FFAR4PARP10FURIN | |
| SCHEMBL795203 | 0.84 | SLC6A4 (0.52) | FFAR4SLC6A4AKR1C3AKR1C1SLC6A2 | |
| SCHEMBL6932018 | 0.84 | FFAR4 (0.49) | FFAR4PARP10SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL10188583 | 0.83 | PARP10 (0.44) | FFAR4PARP10FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| WO-2010086551-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | FFAR4 4424/4885PARP10 3840/4885SLC6A4 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.